Dr. Lee
Endocrinology
Held at 2.5 mg — Week 3 escalation pending review
Propose: 5 mg pen·+2.5 mg from 2.5 mg current
Pen Dose Schedule
Maya is using a fixed-dose prefilled pen — no unit math required.
2.5 mg
completed
2.5 mg
on schedule
2.5 mg
hold — mild nausea
5 mg
jumps — may cause nausea
5 mg
pending approval
5 mg
on schedule
5 mg
planned if tolerated
10 mg
on schedule
Why hold at 2.5 mg? Standard protocols jump from 2.5 mg directly to 5.0 mg. First Dose Health holds the dose when mild nausea is detected, giving the body time to adjust before escalating — keeping patients on track longer.
Patient Response
Week 2 Symptom Summary
Nausea
1/3
Mild
Reflux
0/3
None
Dizziness
0/3
None
Constipation
0/3
None
Held Week 2 — reassess for Week 3
Nausea 1/3 resolved by Day 14. Weight loss on track at −1.6 lbs. Safe to escalate to 5.0 mg pen.
Safety Rules
Nausea resolved to ≤ 1/3
Was 1/3, resolved by Wk2 end
No new onset of severe symptoms
No severe symptoms
Weight change within expected range
−1.6 lbs (expected: −1 to −4 lbs)
Patient completed check-in on time
Submitted Day 14
Fixed-dose pen — no unit calculation required
5.0 mg pen (single-dose prefilled)
Pen patient note
Maya uses a prefilled single-dose 5.0 mg pen. Unlike vial patients, no unit calculation is required — the dose is fixed. Approval here authorizes use of the next pen tier (5.0 mg). No syringe or concentration data applies.
Audit Trail
Complete clinical activity log
Intake form received from Alex Rivera
Risk assessment generated: 3 flags identified
Micro-titration plan drafted: 2.5 mg start, 0.5 mg weekly steps
Reviewed plan, approved Week 1 dose (2.5 mg / 25 units)
Completed injection and symptom check-in
Symptom analysis: Nausea mild (1/3), all others 0. Safe to escalate.
Proposed Week 2 dose: 3.0 mg / 30 units -- awaiting clinician review